Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | C634F |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | RET C634F lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C634F is transforming in cell culture (PMID: 9230192), and therefore, is predicted to lead to a gain of Ret protein function. |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET act mut RET C634F RET mutant RET C634X RET C634F |
Transcript | NM_020975.6 |
gDNA | chr10:g.43114501G>T |
cDNA | c.1901G>T |
Protein | p.C634F |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_020630 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_020975 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_020630.5 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406744.1 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406783.1 | chr10:g.43123796G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43114501G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
NM_001406786.1 | chr10:g.43123796G>T | c.1901G>T | p.C634F | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634F | medullary thyroid carcinoma | predicted - sensitive | Sorafenib | Case Reports/Case Series | Actionable | In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568; NCT00390325). | 20368568 |
RET C634F | malignant pheochromocytoma | predicted - sensitive | Selpercatinib | Case Reports/Case Series | Actionable | In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in a partial response with treatment lasting 37 months in a patient with metastatic pheochromocytoma harboring germline RET C634F (PMID: 38661071; NCT03157128). | 38661071 |